Back to Search
Start Over
Enhanced Bioavailability of Pethidine and Pentazocine in Patients with Cirrhosis of the Liver*
- Source :
- Australian and New Zealand Journal of Medicine. 10:515-519
- Publication Year :
- 1980
- Publisher :
- Wiley, 1980.
-
Abstract
- We studied the bioavailability and disposition kinetics of pethidine and pentazocine in patients with alcoholic cirrhosis and age-matched healthy subjects. In the presence of liver disease, the bioavailability of pethidine was 31% and pentazocine 233% greater than in normals. Systemic clearance was approximately half and terminal half-life double normal for both drugs, whereas volumes of distribution were unchanged. Because of greater bioavailability, oral doses of pethidine and pentazocine should be reduced substantially in patients with cirrhosis. When multiple oral or parenteral doses are required, dosing interval should be lengthened or repeated doses reduced below initial doses because of lower systemic clearance.
- Subjects :
- Adult
Male
Pentazocine
Alcoholic liver disease
Cirrhosis
Meperidine
Metabolic Clearance Rate
Administration, Oral
Biological Availability
Liver disease
Liver Cirrhosis, Alcoholic
Internal Medicine
medicine
Humans
Distribution (pharmacology)
Dose-Response Relationship, Drug
business.industry
Middle Aged
medicine.disease
Bioavailability
Pethidine
Kinetics
Dose–response relationship
Anesthesia
Injections, Intravenous
business
Half-Life
medicine.drug
Subjects
Details
- ISSN :
- 00048291
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- Australian and New Zealand Journal of Medicine
- Accession number :
- edsair.doi.dedup.....e855031a676133a5e33459636411efb1